Zoledro-Denk 4mg/5ml
Add to WishlistCompositon : Zoledronic acid 4mg
Compositon : Zoledronic acid 4mg
Benefits:
One vial with 5 ml concentrate contains 4 mg zoledronic acid (as monohydrate)
Zoledro-Denk prevents skeletal related events in patients with advanced malignancies involving bone fractures in patients with cancers, and treats tumor-induced hypercalcemia, osteoporosis (post-menopausal women and in men; even with a recent low-trauma hip fracture; also associated with long-term systemic glucocorticoid therapy) and Paget’s disease of the bone
Strong inhibition of osteoclastic bone resorption
Showed significant benefit in osteoporosis as well as reduction in mortality after hip fraction
Size : 5ml/vial
Description
Zoledro-Denk 4mg/5ml
Compositon : Zoledronic acid 4mg
Benefits:
One vial with 5 ml concentrate contains 4 mg zoledronic acid (as monohydrate)
Zoledro-Denk prevents skeletal related events in patients with advanced malignancies involving bone fractures in patients with cancers, and treats tumor-induced hypercalcemia, osteoporosis (post-menopausal women and in men; even with a recent low-trauma hip fracture; also associated with long-term systemic glucocorticoid therapy) and Paget’s disease of the bone
Strong inhibition of osteoclastic bone resorption
Showed significant benefit in osteoporosis as well as reduction in mortality after hip fraction
Add a review